Scott J Cameron1, Sara K Ture1, Deanne Mickelsen1, Enakshi Chakrabarti1, Kristina L Modjeski1, Scott McNitt1, Michael Seaberry1, David J Field1, Nhat-Tu Le1, Jun-Ichi Abe1, Craig N Morrell2. 1. From Aab Cardiovascular Research Institute, University of Rochester School of Medicine, NY (S.J.C., S.K.T., D.M., E.C., K.L.M., M.S., D.J.F., C.N.M.); Department of Medicine (S.J.C., C.N.M.) and Heart Research Follow-Up Program (S.M.), Division of Cardiology, University of Rochester School of Medicine, NY; and Department of Cardiology Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston (N.-T.L., J.-i.A.). 2. From Aab Cardiovascular Research Institute, University of Rochester School of Medicine, NY (S.J.C., S.K.T., D.M., E.C., K.L.M., M.S., D.J.F., C.N.M.); Department of Medicine (S.J.C., C.N.M.) and Heart Research Follow-Up Program (S.M.), Division of Cardiology, University of Rochester School of Medicine, NY; and Department of Cardiology Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston (N.-T.L., J.-i.A.). Craig_Morrell@URMC.Rochester.edu.
Abstract
BACKGROUND: Platelets have a pathophysiologic role in the ischemic microvascular environment of acute coronary syndromes. In comparison with platelet activation in normal healthy conditions, less attention is given to mechanisms of platelet activation in diseased states. Platelet function and mechanisms of activation in ischemic and reactive oxygen species-rich environments may not be the same as in normal healthy conditions. Extracellular regulated protein kinase 5 (ERK5) is a mitogen-activated protein kinase family member activated in hypoxic, reactive oxygen species-rich environments and in response to receptor-signaling mechanisms. Prior studies suggest a protective effect of ERK5 in endothelial and myocardial cells after ischemia. We present evidence that platelets express ERK5 and that platelet ERK5 has an adverse effect on platelet activation via selective receptor-dependent and receptor-independent reactive oxygen species-mediated mechanisms in ischemic myocardium. METHODS AND RESULTS: Using isolated human platelets and a mouse model of myocardial infarction (MI), we found that platelet ERK5 is activated post-MI and that platelet-specific ERK5(-/-) mice have less platelet activation, reduced MI size, and improved post-MI heart function. Furthermore, the expression of downstream ERK5-regulated proteins is reduced in ERK5(-/-) platelets post-MI. CONCLUSIONS: ERK5 functions as a platelet activator in ischemic conditions, and platelet ERK5 maintains the expression of some platelet proteins after MI, leading to infarct expansion. This demonstrates that platelet function in normal healthy conditions is different from platelet function in chronic ischemic and inflammatory conditions. Platelet ERK5 may be a target for acute therapeutic intervention in the thrombotic and inflammatory post-MI environment.
BACKGROUND: Platelets have a pathophysiologic role in the ischemic microvascular environment of acute coronary syndromes. In comparison with platelet activation in normal healthy conditions, less attention is given to mechanisms of platelet activation in diseased states. Platelet function and mechanisms of activation in ischemic and reactive oxygen species-rich environments may not be the same as in normal healthy conditions. Extracellular regulated protein kinase 5 (ERK5) is a mitogen-activated protein kinase family member activated in hypoxic, reactive oxygen species-rich environments and in response to receptor-signaling mechanisms. Prior studies suggest a protective effect of ERK5 in endothelial and myocardial cells after ischemia. We present evidence that platelets express ERK5 and that platelet ERK5 has an adverse effect on platelet activation via selective receptor-dependent and receptor-independent reactive oxygen species-mediated mechanisms in ischemic myocardium. METHODS AND RESULTS: Using isolated human platelets and a mouse model of myocardial infarction (MI), we found that platelet ERK5 is activated post-MI and that platelet-specific ERK5(-/-) mice have less platelet activation, reduced MI size, and improved post-MI heart function. Furthermore, the expression of downstream ERK5-regulated proteins is reduced in ERK5(-/-) platelets post-MI. CONCLUSIONS:ERK5 functions as a platelet activator in ischemic conditions, and platelet ERK5 maintains the expression of some platelet proteins after MI, leading to infarct expansion. This demonstrates that platelet function in normal healthy conditions is different from platelet function in chronic ischemic and inflammatory conditions. Platelet ERK5 may be a target for acute therapeutic intervention in the thrombotic and inflammatory post-MI environment.
Authors: Xiao-Jun Du; Leonard Shan; Xiao-Ming Gao; Helen Kiriazis; Yang Liu; Abhirup Lobo; Geoffrey A Head; Anthony M Dart Journal: Thromb Haemost Date: 2010-11-05 Impact factor: 5.249
Authors: Norbert Degousee; Jeremy Simpson; Shafie Fazel; Klaus Scholich; Denis Angoulvant; Carlo Angioni; Helmut Schmidt; Marina Korotkova; Eva Stefanski; Xing-Hua Wang; Thomas F Lindsay; Efrat Ofek; Sandra Pierre; Jagdish Butany; Per-Johan Jakobsson; Armand Keating; Ren-Ke Li; Matthias Nahrendorf; Gerd Geisslinger; Peter H Backx; Barry B Rubin Journal: Circulation Date: 2012-05-15 Impact factor: 29.690
Authors: John A Bennett; Sara K Ture; Rachel A Schmidt; Michael A Mastrangelo; Scott J Cameron; Lara E Terry; David I Yule; Craig N Morrell; Charles J Lowenstein Journal: J Pharmacol Exp Ther Date: 2019-02-14 Impact factor: 4.030
Authors: Rachel A Schmidt; Craig N Morrell; Frederick S Ling; Preya Simlote; Genaro Fernandez; David Q Rich; David Adler; Joe Gervase; Scott J Cameron Journal: Transl Res Date: 2017-12-02 Impact factor: 7.012
Authors: Moua Yang; Brian C Cooley; Wei Li; Yiliang Chen; Jeannette Vasquez-Vivar; Na'il O Scoggins; Scott J Cameron; Craig N Morrell; Roy L Silverstein Journal: Blood Date: 2017-03-23 Impact factor: 22.113
Authors: Scott J Cameron; Doran S Mix; Sara K Ture; Rachel A Schmidt; Amy Mohan; Daphne Pariser; Michael C Stoner; Punit Shah; Lijun Chen; Hui Zhang; David J Field; Kristina L Modjeski; Sandra Toth; Craig N Morrell Journal: Arterioscler Thromb Vasc Biol Date: 2018-05-03 Impact factor: 8.311
Authors: Moua Yang; Andaleb Kholmukhamedov; Marie L Schulte; Brian C Cooley; Na'il O Scoggins; Jeremy P Wood; Scott J Cameron; Craig N Morrell; Shawn M Jobe; Roy L Silverstein Journal: Blood Adv Date: 2018-11-13
Authors: Zachary T Hilt; Daphne N Pariser; Sara K Ture; Amy Mohan; Pearl Quijada; Akua A Asante; Scott J Cameron; Julie A Sterling; Alyssa R Merkel; Andrew L Johanson; Jermaine L Jenkins; Eric M Small; Kathleen E McGrath; James Palis; Michael R Elliott; Craig N Morrell Journal: JCI Insight Date: 2019-03-07